PureTech Health (PRTC) Non-Current Debt (2020 - 2021)
PureTech Health (PRTC) reported Non-Current Debt of $14.3 million for Q4 2021, down 3.76% year-over-year from $14.8 million in Q4 2020, and down 3.76% on a QoQ basis from $14.8 million in Q4 2020.
PureTech Health (PRTC) has 2 years of Non-Current Debt data on file, last reported at $14.3 million in Q4 2021.
- Quarterly Non-Current Debt fell 3.76% year-over-year to $14.3 million in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $14.3 million (down 3.76% YoY) and the FY2021 annual result came in at $14.3 million, down 3.76% from the prior year.
- Non-Current Debt retreated to $14.3 million in Q4 2021 per PRTC's latest filing, from $14.8 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $14.8 million in Q4 2020 and bottomed at $14.3 million in Q4 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 319.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | 105.94 Mn |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | - |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 1.99 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | - |
| 10 | PureTech Health | 86.36 Mn | -190.94 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 14.26 Mn |
| Dec 31, 2021 | 14.26 Mn |
| Dec 31, 2020 | 14.82 Mn |
| Dec 31, 2020 | 14.82 Mn |